Future Fund: Breakthrough is £375 million UK-wide programme which encourages private investors to co-invest in high-growth, innovative firms.
The programme makes equity co-investments with private sector investors in growth stage R&D-intensive British companies operating in breakthrough technology sectors. The minimum total investment round size is £30 million. The maximum Future Fund: Breakthrough share of an investment round is 30%.
It is a separate programme to the now closed Future Fund that provided convertible loans, valued up to £5 million, to a broad range of innovative companies to address the funding challenges caused by Covid-19.
For full details of the Future Fund: Breakthrough, including both company and lead investor eligibility criteria, please see the ‘For companies’ and ‘For investors’ pages on the British Patient Capital website.